Overview

Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder

Status:
Recruiting
Trial end date:
2023-06-24
Target enrollment:
Participant gender:
Summary
This is a study of the efficacy and safety of BXCL501 in children and adolescents with acute agitation and either bipolar disorder or schizophrenia.
Phase:
Phase 1
Details
Lead Sponsor:
BioXcel Therapeutics Inc
Collaborator:
Cognitive Research Corporation
Treatments:
Dexmedetomidine